Topic 161

fda sars sofosbuvir approved coronavirus cov drug inhibit epclusa rdrp alovudine virus analogues triphosphate polymerase inhibitors toxicology pharmacology azt velpatasvir pandemic anti replication viral hepatitis coronaviruses alafenamide rna polymerases fluoro tenofovir previously covid rdrps mers terminate 19 health druggable incorporated stranded nucleotide deoxythymidine member structures utr terminators azido molecular radiograph other public molecules base reasoned global world prcc reaction hiv emtricitabine family protease evaluation ncov forms incorporation viruses effective active potential agents emergency therapeutics offer structure chest responsible sbdr silico motifs aids diphosphate mpro antisense spectrum structural same protide exonuclease ability basic 1465 date demonstrated genomes insight report plda ompla

17 items. Top items listed below.

Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase 161 44 1

Nucleotide Analogues as Inhibitors of SARS-CoV Polymerase 161 44 1

Nucleotide Analogues as Inhibitors of Viral Polymerases 161 44 1

Triphosphates of the Two Components in DESCOVY and TRUVADA are Inhibitors of the SARS-CoV-2 Polymerase 161 44 1

Sofosbuvir Terminated RNA is More Resistant to SARS-CoV-2 Proofreader than RNA Terminated by Remdesivir 161 44 1

A Library of Nucleotide Analogues Terminate RNA Synthesis Catalyzed by Polymerases of Coronaviruses Causing SARS and COVID-19 161 44 1

Genome-wide mapping of therapeutically-relevant SARS-CoV-2 RNA structures 161 1

Potentially highly potent drugs for 2019-nCoV 161 44 1

An in silico map of the SARS-CoV-2 RNA Structurome 161 1

Molecules inhibit the enzyme activity of 3-chymotrypsin-like cysteine protease of SARS-CoV-2 virus: the experimental and theory studies 161 44 1

In-depth Bioinformatic Analyses of Human SARS-CoV-2, SARS-CoV, MERS-CoV, and Other Nidovirales Suggest Important Roles of Noncanonical Nucleic Acid Structures in Their Lifecycles 161 37 1

Establishment of a Replicon System for Bourbon Virus and Identification of Small Molecules that Efficiently Inhibit Virus Replication 161 44 41 1

Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic 161 37 1

Impact of emerging mutations on the dynamic properties the SARS-CoV-2 main protease: an in silico investigation 161 91 63 1

The within-host viral kinetics of SARS-CoV-2 161 1

Structure of the full SARS-CoV-2 RNA genome in infected cells 1

Development of a fluorescence based, high-throughput SARS-CoV-2 3CLpro reporter assay 44 1

Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir 44 1

Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases 44 1

Harnessing intrinsic fluorescence for typing of secondary structures of DNA 161 18 8 4

Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening 44 1

Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase 44 1

Identification of novel mutations in RNA-dependent RNA polymerases of SARS-CoV-2 and their implications on its protein structure 37 1

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells 44 1

Crystal structure of calcium bound outer membrane phospholipase A (OmpLA) from Salmonella typhi and in silico anti-microbial screening 161 114 52 12 8

A dynamic regulatory interface on SARS-CoV-2 RNA polymerase 44 1

The FDA-approved gold drug Auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells 44 1

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors 44 1

Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro 44 1

Structure of Mpro from COVID-19 virus and discovery of its inhibitors 44 1

Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19 36 1

Comprehensive in-vivo secondary structure of SARS-CoV-2 genome reveals novel regulatory motifs and mechanisms 1

Development of a simple in vitro assay to identify and evaluate nucleotide analogs against SARS-CoV-2 RNA-dependent RNA polymerase 44 1

Conserved interactions required for in vitro inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 44 1

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease 44 1

Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase 44 1

The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections 44 1

Mapping RNA dependent RNA polymerase activity and immune gene expression using PRO-seq 41 1

Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs 44 1

Structural basis for repurposing a 100-years-old drug suramin for treating COVID-19 44 1

A Transferable Deep Learning Approach to Fast Screen Potent Antiviral Drugs against SARS-CoV-2 44 1

When Darkness Becomes a Ray of Light in the Dark Times: Understanding the COVID-19 via the Comparative Analysis of the Dark Proteomes of SARS-CoV-2, Human SARS and Bat SARS-Like Coronaviruses 103 1

Functional and druggability analysis of the SARS-CoV-2 proteome 44 1

Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir 44 1

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites 1

Identification of a critical horseshoe-shaped region in the nsp5 (Mpro, 3CLpro) protease interdomain loop (IDL) of coronavirus mouse hepatitis virus (MHV) 1

Structural and biochemical characterization of nsp12-nsp7-nsp8 core polymerase complex from COVID-19 virus 1

6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities 44 7 1

TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets 44 1

The Strand-biased Transcription of SARS-CoV-2 and Unbalanced Inhibition by Remdesivir 1

Antiviral activity of Glucosylceramide synthase inhibitors against SARS-CoV-2 and other RNA virus infections 44 1

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening 44 1

Broad-spectrum antiviral activity of naproxen: from Influenza A to SARS-CoV-2 Coronavirus 44 1

Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate 44 1

Comparative analysis of coronavirus genomic RNA structure reveals conservation in SARS-like coronaviruses 1

Nitazoxanide and JIB-04 have broad-spectrum antiviral activity and inhibit SARS-CoV-2 replication in cell culture and coronavirus pathogenesis in a pig model 44 1

A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals 44 1

Role of 1'-Ribose Cyano Substitution for Remdesivir to Effectively Inhibit both Nucleotide Addition and Proofreading in SARS-CoV-2 Viral RNA Replication 44 1

Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2 44 7 1

Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction 36 1

SARS CoV-2 nucleocapsid protein forms condensates with viral genomic RNA 103 1

Coarse-grained molecular simulations of the binding of the SARS-CoV 2 spike protein RBD to the ACE2 receptor 36 1

In-silico analysis of SARS-CoV-2 genomes: Insights from SARS encoded non-coding RNAs 37 1

Substrate specificity profiling of SARS-CoV-2 main protease enables design of activity-based probes for patient-sample imaging 44 1

Discovery of Clioquinol and Analogues as Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, ACE2 and ACE2 - Spike Protein Interaction In Vitro 44 36 1

Whole genome identification of potential G-quadruplexes and analysis of the G-quadruplex binding domain for SARS-CoV-2 103 1

Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo 44 1

Structural basis for the inhibition of the SARS-CoV-2 RNA-dependent RNA polymerase by favipiravir-RTP 51 44 8 1

Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2 44 1

Massive-scale biological activity-based modeling identifies novel antiviral leads against SARS-CoV-2 44 1

Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection 44 1

Pre-clinical search of SARS-CoV-2 inhibitors and their combinations in approved drugs to tackle COVID-19 pandemic 44 1

Machine intelligence design of 2019-nCoV drugs 103 44 1

Structure of SARS-CoV-2 main protease in the apo state reveals the inactive conformation 44 1

The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2 44 1

Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2 44 1

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing 44 1

Alignment of virus-host protein-protein interaction networks by integer linear programming: SARS-CoV-2 1

Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro 44 1

FDA approved calcium channel blockers inhibit SARS-CoV-2 infectivity in epithelial lung cells 44 1

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease. 44 1

Sofosbuvir protects human brain organoids against SARS-CoV-2 44 1

A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19 44 1

Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. 44 1

Structural and Evolutionary Analysis Indicate that the SARS-CoV-2 Mpro is an Inconvenient Target for Small-Molecule Inhibitors Design 44 1

Structural insight into the putative role of novel SARS CoV-2 E protein in viral infection: a potential target for LAV development and therapeutic strategies 7 1

Structure Basis for Inhibition of SARS-CoV-2 by the Feline Drug GC376 44 1

In vivo structural characterization of the whole SARS-CoV-2 RNA genome identifies host cell target proteins vulnerable to re-purposed drugs 1

Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules 44 1

The potential role of miR-21-3p in coronavirus-host interplay 7 1

Discovery of potent inhibitors of PLproCoV2 by screening libraries of selenium-containing compounds 44 1

The global and local distribution of RNA structure throughout the SARS-CoV-2 genome 1

Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro 44 1

Structural analysis of the SARS-CoV-2 methyltransferase complex involved in coronaviral RNA cap creation 44 1

Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2 36 1

A Small interfering RNA lead targeting RNA-dependent RNA-polymerase effectively inhibit the SARS-CoV-2 infection in Golden Syrian hamster and Rhesus macaque 103 73 1

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19 44 1

Identification of TMEM106B as proviral host factor for SARS-CoV-2 73 1

Metaviromic identification of genetic hotspots of coronavirus pathogenicity using machine learning 37 1

A Fluorescence-based High Throughput-Screening assay for the SARS-CoV RNA synthesis complex 6 1